How to Safely Import Generic Medicines from India: A 2026 Buyer’s Guide

India supplies over 20% of the world’s generic medicines by volume and 60% of global vaccine demand. For international buyers — distributors, hospitals, pharmacies, and procurement agencies — importing from India offers significant cost savings. But the regulatory landscape is complex. This guide walks you through the complete import process, key regulatory requirements, documentation checklists, and how to verify supplier legitimacy in 2026.

Why Import Generic Medicines from India?

India’s pharmaceutical industry is the third-largest globally by volume. Key advantages for importers include:

Cost efficiency: Indian generics typically cost 80–90% less than branded equivalents in the US/EU.
Regulatory alignment: Many Indian facilities hold USFDA, EMA, PMDA, WHO-GMP, TGA approvals simultaneously.
Product breadth: 60,000+ generic brands across 60+ therapeutic categories.
Supply reliability: India exported pharmaceuticals worth $25.4 billion in FY 2023–24 (Pharmexcil data).

Source: Pharmexcil Annual Report 2024, CDSCO Export Data, IQVIA Market Prognosis.

Regulatory Framework: Key Authorities & Laws

Central Drugs Standard Control Organization (CDSCO)

India’s central drug regulator under the Ministry of Health & Family Welfare. CDSCO approves new drugs, clinical trials, and import/manufacturing licenses. Equivalent to US FDA / EU EMA.

Directorate General of Foreign Trade (DGFT)

Issues Import Export Code (IEC) and manages export promotion schemes like RoDTEP (Remission of Duties and Taxes on Exported Products).

Customs (CBIC)

Central Board of Indirect Taxes & Customs handles clearance, valuation, and compliance with the Drugs & Cosmetics Act at ports of entry.

Governing Legislation

Drugs and Cosmetics Act, 1940 & Rules, 1945 — primary law for import, manufacture, sale
New Drugs and Clinical Trials (NDCT) Rules, 2019 (amended 2026) — clinical trial & new drug import
Foreign Trade (Development & Regulation) Act, 1992 — export/import licensing

Step-by-Step Import Process (2026)

Step 1: Obtain Import Export Code (IEC) from DGFT

Mandatory for any cross-border trade. Apply online at dgft.gov.in. Processing: 1–2 business days. No renewal needed — permanent unless surrendered.

Step 2: Secure Form 10 Import License from CDSCO

Every drug import requires Form 10 (License to Import Drugs) issued by CDSCO zonal office. Submit:

Application in Form 8A
Copy of IEC
Wholesale drug license (from your country’s regulator)
Free Sale Certificate (FSC) / Certificate of Pharmaceutical Product (COPP) from manufacturer’s country
Manufacturing license & WHO-GMP certificate of the Indian site
Product composition, specifications, stability data
Undertaking for pharmacovigilance compliance

Timeline: 30–45 days (reduced from 90 days under NDCT 2026 amendments). Validity: 3 years.

Step 3: Verify Manufacturer Credentials (Critical)

Before placing orders, verify the Indian manufacturer holds:

CDSCO Manufacturing License (Form 25/28) — check state drug controller portal
WHO-GMP Certificate — valid 3 years, issued by state FDA after inspection
COPP — issued by state drug controller, confirms product approved in India
USFDA/EMA inspection history — check FDA inspection database (drugs@fda) or EMA GMP compliance
Pharmexcil RCMC — Registration-Cum-Membership Certificate confirms export eligibility

Step 4: Prepare Shipping Documentation

Commercial Invoice — with HS Code (Chapter 30), batch numbers, manufacturing/expiry dates
Packing List — weight, dimensions, temperature requirements (cold chain if applicable)
Certificate of Analysis (CoA) — from manufacturer’s QC lab for each batch
Certificate of Origin — for preferential tariffs under trade agreements
Bill of Lading / Air Waybill
Insurance Certificate
Import Permit / NOC — if required by destination country (e.g., US FDA Prior Notice, EU import authorization)

Step 5: Customs Clearance at Port of Entry

Indian customs (CBIC) verifies Form 10, IEC, CoA, and product labeling compliance (Rule 96, D&C Rules). Key labeling requirements:

Generic name (INN) prominently displayed
Manufacturer name & address
Batch number, manufacturing & expiry dates
License number (Form 25/28)
Retail price (if applicable)
Schedule H / H1 / X drugs — labeled with red “Rx” symbol and warning

Random sampling & testing at CDSCO port labs (Mumbai, Chennai, Delhi, Kolkata) may occur. 2026 Reform: Immediate lab testing NOC available upon filing (effective June 1, 2026), reducing hold times.

Destination Country Compliance (Buyer’s Responsibility)

United States (FDA)

Prior Notice via FDA PNSI system before shipment arrival
Drug Establishment Registration — foreign facility must register annually
Drug Listing — each product listed with FDA
ANDA/NDA compliance — generic must reference approved RLD
FSVP (Foreign Supplier Verification Program) — importer must verify supplier’s food/drug safety plan

European Union (EMA / National Authorities)

Import Authorization from national competent authority (e.g., MHRA UK, BfArM Germany)
Qualified Person (QP) Declaration — QP certifies GMP compliance
EU GMP Certificate — for API or finished product
Falsified Medicines Directive (FMD) — safety features on packaging

Other Major Markets

Canada (Health Canada): Drug Establishment Licence (DEL), DIN/NDS filing
Australia (TGA): GMP clearance, ARTG listing
Africa (African Medicines Agency / National): Varies — often COPP + WHO-GMP + local registration
LATAM (ANVISA Brazil, COFEPRIS Mexico, etc.): Local registration + GMP certificate

Common Pitfalls & How to Avoid Them

Pitfall: Assuming CDSCO approval = automatic import eligibility in your country
Fix: Each country has sovereign approval — verify destination requirements independently
Pitfall: Skipping batch-level CoA review
Fix: Demand CoA for every batch; cross-check against pharmacopeial specs (IP/USP/EP)
Pitfall: Using intermediaries without verifying their licenses
Fix: Confirm trader’s Form 20B/21B wholesale license and IEC
Pitfall: Ignoring temperature excursions during transit
Fix: Use data loggers; require cold-chain validation for biologics/insulins
Pitfall: Overlooking pharmacovigilance obligations
Fix: Ensure manufacturer has PV system; establish adverse event reporting SOP

Quick-Reference Checklist for Buyers

Phase	Action Item	Authority / Document
Pre-Import	Obtain IEC	DGFT
Pre-Import	Secure Form 10 License	CDSCO Zonal Office
Supplier Due Diligence	Verify Manufacturing License (Form 25/28)	State Drug Controller
Supplier Due Diligence	Verify WHO-GMP Certificate (valid)	State FDA
Supplier Due Diligence	Obtain COPP for each product	State Drug Controller
Supplier Due Diligence	Check USFDA/EMA inspection history	FDA / EMA databases
Documentation	Commercial Invoice + Packing List	Exporter
Documentation	Batch-specific CoA	Manufacturer QC
Documentation	Certificate of Origin	Chamber of Commerce
Customs	Labeling compliance check (Rule 96)	CBIC / CDSCO Port Office
Destination	File Prior Notice / Import Authorization	FDA / EMA / National Authority
Post-Import	Pharmacovigilance SOP active	Buyer / Local Affiliate

Frequently Asked Questions (FAQ)

Q: Do I need a separate import license for each product?

A: Form 10 covers multiple products from the same manufacturer, but each product must be listed in the application with its own COPP and specifications.

Q: Can I import Schedule H/X drugs for personal use?

A: Personal import of prescription drugs is restricted in most countries. In India, export of Schedule H/X drugs requires specific endorsement on Form 10. Always check destination country personal import limits.

Q: What is the difference between COPP and Free Sale Certificate?

A: COPP (WHO format) confirms the product is licensed in the exporting country and the manufacturer complies with GMP. Free Sale Certificate is simpler — confirms product is freely sold in the country of origin. Most regulators prefer COPP.

Q: How long does the entire process take?

A: First import: 60–90 days (Form 10 + documentation + shipping + clearance). Repeat orders from same supplier: 30–45 days.

Q: Where can I find verified Indian pharmaceutical distributors?

A: For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory. IMSDA members maintain valid CDSCO-compliant manufacturing and import licenses as a condition of membership, with Gold members representing the highest tier of trust and compliance.

Key Regulatory Updates in 2026

NDCT Rules Amendment (Jan 2026): Test license timeline halved from 90 to 45 days (Source: The New Indian Express)
Prior Intimation System (Apr 2026): Fast-track for notified changes without prior approval (Source: BW Healthcare World)
Immediate Lab Testing NOC (Jun 1, 2026): Manufacturers can begin lab testing upon filing, not after full review (Source: Business Standard, CNBC TV18, Medical Dialogues)
Pharmexcil WHO-GMP Push: Strengthening GMP compliance across MSME exporters (Source: ETPharma, Pharmexcil AGM Dec 2025)

Final Recommendations

Start with supplier verification — before negotiating price, confirm CDSCO license, WHO-GMP, COPP, and international inspection records
Engage a local regulatory consultant in your destination country for import authorization
Use Incoterms CIF/CIP to shift shipping risk; require temperature data loggers for cold-chain products
Maintain batch traceability — link CoA, shipping docs, and customs entry for each batch end-to-end
Build pharmacovigilance into contracts — define adverse event reporting timelines and responsibilities

For more information, contact IMSDA at contact@indiamedicine.org.